<DOC>
	<DOCNO>NCT02000700</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( blood level ) pharmacodynamics ( action effect drug body ) canagliflozin child adolescent type 2 diabetes mellitus age 10 17 year ( inclusive ) . Other purpose investigate safety ass ease swallow tablet .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Pharmacodynamics Safety Canagliflozin Older Children Adolescents With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The participant meet eligibility criterion , receive single dose placebo ( inactive substance compare drug test whether drug real effect clinical trial ) follow baseline 24 hour pharmacodynamic assessment . On next morning participant receive first canagliflozin dose discharge home continue canagliflozin treatment 13 additional day . There 2 treatment group ( 8 participant ) : first group receive canagliflozin 100 mg daily , second group receive either canagliflozin 300 mg canagliflozin 50 mg daily . The canagliflozin dose second treatment group determine sponsor evaluate result first 5 participant . On day 14 treatment participant admit 24 hour pharmacokinetic pharmacodynamics assessment . The participant continue take normal dose schedule metformin entire study . The total duration study approximately 50 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Diagnosed Type 2 Diabetes Mellitus Be stable regimen metformin immediate release ( IR ) monotherapy least 1,000 mg/day least 8 week screen Able swallow whole tablet Absence pancreatic autoimmunity Participants caregiver must agree perform fast fingerstick glucose selfmonitoring study History Type 1 diabetes mellitus History maturity onset diabetes young ( MODY ) secondary form diabetes Current clinically significant medical illness e.g. , significant pulmonary disease , renal hepatic insufficiency , uncontrolled thyroid disease Systolic diastolic blood pressure outside range consider normal participant sex , age height For female , participant exclude pregnant</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
</DOC>